NO20055516L - Kannabinoidreceptorligander og anvendelser derav - Google Patents

Kannabinoidreceptorligander og anvendelser derav

Info

Publication number: NO20055516L
Authority: NO; Norway
Prior art keywords: receptor ligands; cannabinoid receptor; cannabinoid; mediation; formulas
Prior art date: 2003-04-23

Application number

NO20055516A

Other languages

English (en)

Norwegian (no)

Inventor

Philip Albert Carpino

Robert Lee Dow

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-23

Filing date

2005-11-22

Publication date

2005-11-22

2005-11-22 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2005-11-22 Publication of NO20055516L publication Critical patent/NO20055516L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Child & Adolescent Psychology (AREA)
Nutrition Science (AREA)
Rheumatology (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Gynecology & Obstetrics (AREA)
Reproductive Health (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyrane Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Peptides Or Proteins (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NO20055516A 2003-04-23 2005-11-22 Kannabinoidreceptorligander og anvendelser derav NO20055516L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US46490803P	2003-04-23	2003-04-23
PCT/IB2004/001357 WO2004094421A1 (fr)	2003-04-23	2004-04-13	Ligands de recepteurs cannabinoides et leurs applications

Publications (1)

Publication Number	Publication Date
NO20055516L true NO20055516L (no)	2005-11-22

Family

ID=33310977

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20055516A NO20055516L (no)	2003-04-23	2005-11-22	Kannabinoidreceptorligander og anvendelser derav

Country Status (31)

Country	Link
US (1)	US20040214856A1 (fr)
EP (1)	EP1622903B1 (fr)
JP (1)	JP2006524225A (fr)
KR (1)	KR20060006048A (fr)
CN (1)	CN1809566A (fr)
AP (1)	AP2005003427A0 (fr)
AR (1)	AR044037A1 (fr)
AT (1)	ATE409700T1 (fr)
AU (1)	AU2004232552A1 (fr)
BR (1)	BRPI0409791A (fr)
CA (1)	CA2521538A1 (fr)
CL (1)	CL2004000827A1 (fr)
CO (1)	CO5640084A2 (fr)
DE (1)	DE602004016839D1 (fr)
EA (1)	EA200501504A1 (fr)
EC (1)	ECSP056117A (fr)
ES (1)	ES2309517T3 (fr)
GT (1)	GT200400076A (fr)
IS (1)	IS8054A (fr)
MA (1)	MA27766A1 (fr)
MX (1)	MXPA05011454A (fr)
NL (1)	NL1026027C2 (fr)
NO (1)	NO20055516L (fr)
OA (1)	OA13047A (fr)
PA (1)	PA8600601A1 (fr)
PE (1)	PE20050419A1 (fr)
TN (1)	TNSN05272A1 (fr)
TW (1)	TW200510419A (fr)
UY (1)	UY28276A1 (fr)
WO (1)	WO2004094421A1 (fr)
ZA (1)	ZA200508568B (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE375349T1 (de) *	2002-08-02	2007-10-15	Merck & Co Inc	Substituierte furo(2,3-b)pyridin derivate
EP1546115A4 (fr)	2002-09-27	2010-08-04	Merck Sharp & Dohme	Pyrimidines substituees
EP1603585A2 (fr) *	2003-03-14	2005-12-14	Bristol-Myers Squibb Company	Polynucleotide codant un nouveau variant de recepteur de hm74, hgprbmy74 couple a une proteine g humaine
US7268133B2 (en)	2003-04-23	2007-09-11	Pfizer, Inc. Patent Department	Cannabinoid receptor ligands and uses thereof
US7145012B2 (en)	2003-04-23	2006-12-05	Pfizer Inc.	Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) *	2003-04-23	2006-11-28	Pfizer Inc.	Cannabiniod receptor ligands and uses thereof
CA2524397A1 (fr) *	2003-05-07	2004-11-18	Pfizer Products Inc.	Ligands de recepteurs cannabinoides et leurs applications
US7232823B2 (en) *	2003-06-09	2007-06-19	Pfizer, Inc.	Cannabinoid receptor ligands and uses thereof
US20050026983A1 (en) *	2003-07-30	2005-02-03	Pfizer Inc	Imidazole compounds and uses thereof
WO2005047285A1 (fr) *	2003-11-04	2005-05-26	Merck & Co., Inc.	Derives de naphtyridinone substitues
US7151097B2 (en) *	2003-11-07	2006-12-19	Pfizer Inc.	Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
UY28945A1 (es)	2004-06-09	2006-01-31	Glaxo Group Ltd	Derivados de pirrolopiridina
US20060025448A1 (en)	2004-07-22	2006-02-02	Cadila Healthcare Limited	Hair growth stimulators
AU2005302697B2 (en) *	2004-10-27	2012-09-13	Janssen Pharmaceutica, N.V.	Tetrahydro pyridinyl pyrazole cannabinoid modulators
CA2589695A1 (fr) *	2004-12-17	2006-06-22	Eli Lilly And Company	Derives de thiazolopyridinone en tant qu'antagonistes de recepteur mch
CA2603104A1 (fr)	2005-03-31	2006-10-12	Janssen Pharmaceutica N.V.	Modulateurs de cannabinoides a base de tetrahydrothiopyranopyrazole
CA2605479A1 (fr) *	2005-04-20	2006-10-26	Pfizer Products Inc.	Composes acylaminobicycliques comportant un heteroatome et leurs utilisations
CA2609783A1 (fr) *	2005-05-27	2006-12-07	Pfizer Products Inc.	Polytherapie pour le traitement de l'obesite ou le maintien du poids apres une perte ponderale
PE20070239A1 (es) *	2005-08-09	2007-04-01	Glaxo Group Ltd	Derivados de imidazopiridina con actividad sobre los receptores cannabinoides
WO2007046550A1 (fr) *	2005-10-21	2007-04-26	Mitsubishi Tanabe Pharma Corporation	Composes pyrazole presentant une activite antagoniste du recepteur cannabinoide (cb1)
US20090264470A1 (en) *	2006-02-21	2009-10-22	Bennett Teresa A	CB1 Antagonists and Inverse Agonists
AU2007283113A1 (en)	2006-08-08	2008-02-14	Sanofi-Aventis	Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
US20080108574A1 (en) *	2006-09-27	2008-05-08	Braincells, Inc.	Melanocortin receptor mediated modulation of neurogenesis
PE20090142A1 (es) *	2007-04-11	2009-02-19	Merck & Co Inc	Derivados de furo[2,3-b] piridina sustituidos como moduladores del receptor canabinoide-1
EP2025674A1 (fr)	2007-08-15	2009-02-18	sanofi-aventis	Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
EP2242745A1 (fr) *	2008-02-07	2010-10-27	Sanofi-Aventis	Nouvelles imidazolidines substituées par un phényle, procédé de production, médicaments contenant ces composés et leur utilisation
EP2310372B1 (fr)	2008-07-09	2012-05-23	Sanofi	Composés hétérocycliques, leur procédé de préparation, médicaments les contenant et leur utilisation
JO2870B1 (en)	2008-11-13	2015-03-15	ميرك شارب اند دوهم كورب	Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
WO2010068601A1 (fr)	2008-12-08	2010-06-17	Sanofi-Aventis	Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
ES2443016T3 (es)	2009-08-26	2014-02-17	Sanofi	Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo
EP2480082A4 (fr)	2009-09-25	2014-01-15	Merck Sharp & Dohme	Aminopipéridines substituées utilisées en tant qu'inhibiteurs de la dipeptidyl peptidase-iv dans le cadre du traitement du diabète
EP2582709B1 (fr)	2010-06-18	2018-01-24	Sanofi	Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8809325B2 (en)	2011-03-08	2014-08-19	Sanofi	Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
US8809324B2 (en)	2011-03-08	2014-08-19	Sanofi	Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8828995B2 (en)	2011-03-08	2014-09-09	Sanofi	Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8846666B2 (en)	2011-03-08	2014-09-30	Sanofi	Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2766349B1 (fr)	2011-03-08	2016-06-01	Sanofi	Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
EP2683699B1 (fr)	2011-03-08	2015-06-24	Sanofi	Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
EP2683705B1 (fr)	2011-03-08	2015-04-22	Sanofi	Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
EP2683700B1 (fr)	2011-03-08	2015-02-18	Sanofi	Dérivés d'oxathiazine tétra-substitués, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation
WO2012120057A1 (fr)	2011-03-08	2012-09-13	Sanofi	Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation
WO2013175417A1 (fr)	2012-05-24	2013-11-28	Novartis Ag	Composés pyrrolopyrrolidinones
WO2014115080A1 (fr)	2013-01-22	2014-07-31	Novartis Ag	Composés pyrazolo[3,4-d]pyrimidinone utilisés en tant qu'inhibiteurs de l'interaction p53/mdm2
US9403827B2 (en)	2013-01-22	2016-08-02	Novartis Ag	Substituted purinone compounds
BR112015029491A2 (pt) *	2013-05-27	2017-07-25	Novartis Ag	derivados de imidazopirrolidinona e seu uso no tratamento de doença
MX2015016421A (es)	2013-05-28	2016-03-03	Novartis Ag	Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
ES2650562T3 (es)	2013-05-28	2018-01-19	Novartis Ag	Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades
EP3071571A1 (fr)	2013-11-21	2016-09-28	Novartis AG	Dérivés de pyrrolopyrrolone et leur utilisation en tant qu'inhibiteurs de protéines bet
KR20240036709A (ko) *	2016-03-11	2024-03-20	에이씨 이뮨 에스에이	진단 및 치료를 위한 바이사이클릭 화합물
CN105878251B (zh) *	2016-04-22	2019-04-09	上海市同济医院	帕金森病动物模型的制备方法及其用途
EP3630774B1 (fr)	2017-05-31	2022-11-23	ChemoCentryx, Inc.	Cycles 5-5 fusionnés utilisés en tant qu'inhibiteurs de c5a
MX392259B (es) *	2017-05-31	2025-03-24	Chemocentryx Inc	ANILLOS 6-5 FUSIONADOS COMO INHIBIDORES C5a
JP7254082B2 (ja)	2017-12-22	2023-04-07	ケモセントリックス，インコーポレイティド	Ｃ５ａＲ阻害剤としてのジアリール置換６，５－縮合環化合物
IL275516B2 (en)	2017-12-22	2023-12-01	Chemocentryx Inc	Diaryl substituted 5,5-fused ring compounds as c5ar inhibitors
KR102809631B1 (ko) *	2018-04-02	2025-05-16	케모센트릭스, 인크.	융합된-바이사이클릭 C5aR 길항제의 프로드러그
BR112022021774A2 (pt) *	2020-05-07	2022-12-13	Ac Immune Sa	Compostos para diagnóstico
CN117460731A (zh) *	2021-06-11	2024-01-26	劲方医药科技(上海)有限公司	杂环内酰胺类化合物，其制法与医药上的用途
IL310747A (en) *	2021-08-11	2024-04-01	Landos Biopharma Inc	TETRAHYDROPYRAZOLOPYRIDINE-ANALOG LIGANDS OF NLRX1 AND THEIR USES

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3365459A (en) *	1964-09-08	1968-01-23	Ciba Geigy Corp	Certain tetrahydro pyrazolo-pyridine and pyrazolo-piperidine derivatives
US3340269A (en) *	1964-09-08	1967-09-05	Ciba Geigy Corp	1-substituted 4-acyl-2, 3-dioxo-piperidine
GB8613591D0 (en) *	1986-06-04	1986-07-09	Roussel Lab Ltd	Chemical compounds
DE3775527D1 (de) *	1986-10-22	1992-02-06	Ciba Geigy Ag	1,5-diphenylpyrazol-3-carbonsaeurederivate zum schuetzen von kulturpflanzen.
PH27357A (en) *	1989-09-22	1993-06-21	Fujisawa Pharmaceutical Co	Pyrazole derivatives and pharmaceutical compositions comprising the same
FR2665898B1 (fr) *	1990-08-20	1994-03-11	Sanofi	Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2692575B1 (fr) *	1992-06-23	1995-06-30	Sanofi Elf	Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2714057B1 (fr) *	1993-12-17	1996-03-08	Sanofi Elf	Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
US5596106A (en) *	1994-07-15	1997-01-21	Eli Lilly And Company	Cannabinoid receptor antagonists
FR2741621B1 (fr) *	1995-11-23	1998-02-13	Sanofi Sa	Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
FR2742148B1 (fr) *	1995-12-08	1999-10-22	Sanofi Sa	Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
EP0971588B1 (fr) *	1997-01-21	2004-03-17	Smithkline Beecham Corporation	Nouveaux modulateurs de recepteurs de cannabinoides
FR2758723B1 (fr) *	1997-01-28	1999-04-23	Sanofi Sa	Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
FR2761266B1 (fr) *	1997-03-28	1999-07-02	Sanofi Sa	Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
IL141769A0 (en) *	1998-09-11	2002-03-10	Aventis Pharma Sa	Azetidine derivatives, preparation and medicines containing them
FR2789079B3 (fr) *	1999-02-01	2001-03-02	Sanofi Synthelabo	Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
JP2004502642A (ja) *	2000-02-11	2004-01-29	ブリストル−マイヤーズ　スクイブ　カンパニー	カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用
US6355631B1 (en) *	2000-03-03	2002-03-12	Aventis Pharma S.A.	Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
US6566356B2 (en) *	2000-03-03	2003-05-20	Aventis Pharma S.A.	Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
US6479479B2 (en) *	2000-03-03	2002-11-12	Aventis Pharma S.A.	Azetidine derivatives, their preparation and pharmaceutical compositions containing them
CN1205188C (zh) *	2000-03-23	2005-06-08	索尔瓦药物有限公司	具有cb1－拮抗活性的4,5－二氢－1h－吡唑衍生物
US20020019421A1 (en) *	2000-07-05	2002-02-14	Roni Biberman	Compositions and therapy for substance addiction
US20020091114A1 (en) *	2000-10-04	2002-07-11	Odile Piot-Grosjean	Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
WO2003007887A2 (fr) *	2001-07-20	2003-01-30	Merck & Co., Inc.	Imidazoles substitues servant de modulateurs de recepteurs de cannabinoides
US6509367B1 (en) *	2001-09-22	2003-01-21	Virginia Commonwealth University	Pyrazole cannabinoid agonist and antagonists
US20030139386A1 (en) *	2001-12-21	2003-07-24	Sophie Cote	Pharmaceutical compositions based on azetidine derivatives
US6825209B2 (en) *	2002-04-15	2004-11-30	Research Triangle Institute	Compounds having unique CB1 receptor binding selectivity and methods for their production and use
EP1556373A1 (fr) *	2002-10-18	2005-07-27	Pfizer Products Inc.	Ligands des recepteurs des cannabinoides et applications de ceux-ci
US7129239B2 (en) *	2002-10-28	2006-10-31	Pfizer Inc.	Purine compounds and uses thereof
US7247628B2 (en) *	2002-12-12	2007-07-24	Pfizer, Inc.	Cannabinoid receptor ligands and uses thereof
US7329658B2 (en) *	2003-02-06	2008-02-12	Pfizer Inc	Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) *	2003-02-10	2007-02-13	Pfizer Inc.	Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) *	2003-04-23	2006-11-28	Pfizer Inc.	Cannabiniod receptor ligands and uses thereof
US7268133B2 (en) *	2003-04-23	2007-09-11	Pfizer, Inc. Patent Department	Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) *	2003-04-23	2006-12-05	Pfizer Inc.	Cannabinoid receptor ligands and uses thereof

2004
- 2004-04-12 US US10/823,152 patent/US20040214856A1/en not_active Abandoned
- 2004-04-13 AT AT04727076T patent/ATE409700T1/de not_active IP Right Cessation
- 2004-04-13 BR BRPI0409791-2A patent/BRPI0409791A/pt not_active IP Right Cessation
- 2004-04-13 ES ES04727076T patent/ES2309517T3/es not_active Expired - Lifetime
- 2004-04-13 EP EP04727076A patent/EP1622903B1/fr not_active Expired - Lifetime
- 2004-04-13 OA OA1200500291A patent/OA13047A/en unknown
- 2004-04-13 EA EA200501504A patent/EA200501504A1/ru unknown
- 2004-04-13 MX MXPA05011454A patent/MXPA05011454A/es unknown
- 2004-04-13 JP JP2006506562A patent/JP2006524225A/ja not_active Abandoned
- 2004-04-13 AP AP2005003427A patent/AP2005003427A0/xx unknown
- 2004-04-13 CA CA002521538A patent/CA2521538A1/fr not_active Abandoned
- 2004-04-13 DE DE602004016839T patent/DE602004016839D1/de not_active Expired - Fee Related
- 2004-04-13 KR KR1020057020010A patent/KR20060006048A/ko not_active Ceased
- 2004-04-13 CN CNA2004800175674A patent/CN1809566A/zh active Pending
- 2004-04-13 AU AU2004232552A patent/AU2004232552A1/en not_active Abandoned
- 2004-04-13 WO PCT/IB2004/001357 patent/WO2004094421A1/fr not_active Ceased
- 2004-04-16 CL CL200400827A patent/CL2004000827A1/es unknown
- 2004-04-20 PE PE2004000389A patent/PE20050419A1/es not_active Application Discontinuation
- 2004-04-20 GT GT200400076A patent/GT200400076A/es unknown
- 2004-04-20 PA PA20048600601A patent/PA8600601A1/es unknown
- 2004-04-21 UY UY28276A patent/UY28276A1/es not_active Application Discontinuation
- 2004-04-21 AR ARP040101339A patent/AR044037A1/es unknown
- 2004-04-22 TW TW093111297A patent/TW200510419A/zh unknown
- 2004-04-23 NL NL1026027A patent/NL1026027C2/nl not_active IP Right Cessation
2005
- 2005-09-29 IS IS8054A patent/IS8054A/is unknown
- 2005-10-21 EC EC2005006117A patent/ECSP056117A/es unknown
- 2005-10-21 MA MA28565A patent/MA27766A1/fr unknown
- 2005-10-21 CO CO05106974A patent/CO5640084A2/es not_active Application Discontinuation
- 2005-10-21 ZA ZA200508568A patent/ZA200508568B/en unknown
- 2005-10-21 TN TNP2005000272A patent/TNSN05272A1/fr unknown
- 2005-11-22 NO NO20055516A patent/NO20055516L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
JP2006524225A (ja)	2006-10-26
KR20060006048A (ko)	2006-01-18
IS8054A (is)	2005-09-29
CN1809566A (zh)	2006-07-26
ZA200508568B (en)	2007-04-25
DE602004016839D1 (de)	2008-11-13
EP1622903B1 (fr)	2008-10-01
AP2005003427A0 (en)	2005-12-31
MXPA05011454A (es)	2005-12-12
NL1026027A1 (nl)	2004-10-27
US20040214856A1 (en)	2004-10-28
WO2004094421A1 (fr)	2004-11-04
CO5640084A2 (es)	2006-05-31
TW200510419A (en)	2005-03-16
GT200400076A (es)	2004-12-16
TNSN05272A1 (fr)	2007-07-10
ECSP056117A (es)	2006-03-01
MA27766A1 (fr)	2006-02-01
BRPI0409791A (pt)	2006-05-30
UY28276A1 (es)	2004-11-30
CL2004000827A1 (es)	2005-03-04
EP1622903A1 (fr)	2006-02-08
AR044037A1 (es)	2005-08-24
EA200501504A1 (ru)	2006-04-28
ES2309517T3 (es)	2008-12-16
ATE409700T1 (de)	2008-10-15
AU2004232552A1 (en)	2004-11-04
PA8600601A1 (es)	2005-05-24
CA2521538A1 (fr)	2004-11-04
OA13047A (en)	2006-11-10
PE20050419A1 (es)	2005-06-18
NL1026027C2 (nl)	2005-07-05

Publication	Publication Date	Title
NO20055516L (no)	2005-11-22	Kannabinoidreceptorligander og anvendelser derav
NO20054407L (no)	2005-12-15	Cannabinoid reseptor ligander og deres anvendelser
NO20052512L (no)	2005-05-25	Purinforbindelser og anvendelse deav som kannabinoiode reseptorligander
NO20054082L (no)	2005-11-04	Pyrazol`1,5-A! 1,3,5! triazinderivater som kannabinoidreseptorligander
NO20055731L (no)	2006-02-06	Cannabinoide reseptorligander og deres anvendelse
EA200802213A1 (ru)	2009-10-30	Способы лечения заболеваний крови
DE602004026113D1 (de)	2010-04-29	Glp-1-verbindungen
MXPA05007938A (es)	2005-09-30	Ligandos de receptores de cannabinoides y usos de los mismos.
TW200503723A (en)	2005-02-01	Cannabinoid receptor ligands and uses thereof
MXPA05011362A (es)	2005-11-28	Ligandos de receptor cannabinoide y usos de los mismos.
DK1656346T3 (da)	2009-06-15	1,2,3,4-tetrasubstituerede indol til behandling af luftvejssygdomme
BR0214309A (pt)	2004-10-13	Derivados aril-1,4-pirazina substituìdos
MXPA05013282A (es)	2006-03-09	Derivados de pirimidina como ligandos del receptor de cannabinoides.
NO20073574L (no)	2007-07-10	Triazolsubstituerte aminobenzofenonforbindelser
EA200301215A1 (ru)	2004-04-29	Лиганды рецепторов 5-ht и их применение
NO20083002L (no)	2008-08-14	Fremgangsmate for anvendelse av CD40-bindende forbindelser
MX2007005205A (es)	2007-05-11	Compuestos biciclicos sulfonilo-sustituidos como moduladores de receptores activados por el proliferador de la peroxisoma.
PA8571001A1 (es)	2003-12-10	2-(2,6-diclorofenil)-diarilimidazoles
EA200600203A1 (ru)	2006-08-25	Производные 2-(хиноксалин-5-илсульфониламино)бензамида в качестве модуляторов сск2
WO2007020502A3 (fr)	2007-04-19	Ligands des recepteurs de cannabinoide et utilisations de ceux-ci
TW200510325A (en)	2005-03-16	2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
MXPA05011922A (es)	2006-02-17	Ligandos del receptor de cannabinoides y sus usos.
UA85559C2 (en)	2009-02-10	Aminobenzophenone compounds
EA200600647A1 (ru)	2006-10-27	Соединения бициклических пиразолила и имидазолила и их применение
NO20062020L (no)	2006-07-10	1-amino-2-oksysubstituerte tetrahydronaftalenderivater, fremgangsmate for fremstilling derav, og deres anvendelse som antiflogistika

Legal Events

Date	Code	Title	Description
2008-11-24	FC2A	Withdrawal, rejection or dismissal of laid open patent application